microdose glp-1 noom launches Proactive Health Program for long-term health Noom Enters Longevity Health Space

Across the 52 weeks of ATTAIN-MAINTAIN, participants treated with orforglipron gained an average of 5 kg (11 lbs) in the tirzpatide group and an average of 1 kg (2.2 lbs) in the semaglutide group

Tirzepatide is a newer medication and is still being assessed for its long-term effects and potential additional benefits, such as cardiovascular outcomes

Medication Tips GLP-1 New Products: Wegovy (semaglutide) Tablets and Multi-Dose Vials of Mounjaro and Zepbound (tirzepatide) Reuters reports that Novo Nordisks new Wegovy (semaglutide) pill is a hit, with total prescriptions filled during its first full week on the market topping 18,000

Propensity score matching (PSM) was employed to create two cohorts: A GLP-1 agonists group and a control group without GLP-1 agonists usage